未登录

H

Hans-Georg Lerchen

Bayer AG

H指数:16

被引数:660

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Addressing drug metabolism and pharmacokinetics (DMPK) challenges of small molecule-drug conjugates (SMDCs)

CANCER RESEARCH

IF16.6

2024-03-220

PRE

Innovations in ADC technology platform with legumain-cleavable KSP-inhibitor payloads adaptable to various aspects of cancer biology

CANCER RESEARCH

IF16.6

2024-03-220

PRE

Preclinical characterization and prediction of human pharmacokinetics and efficacious dose for VIP236, a novel alpha V beta 3 binding small molecule-drug conjugate (SMDC)

MOLECULAR CANCER THERAPEUTICS

IF5.5

2023-12-010

PRE

CXCR5 is a very promising drug target for the development of antibody-drug conjugates to treat patients with lymphoma

CANCER RESEARCH

IF16.6

2023-04-040

PRE

Synthesis and characterization of novel small molecule drug conjugates with different payloads designed to be released in tumor microenvironment by neutrophil elastase

CANCER RESEARCH

IF16.6

2023-04-040

PRE

VIP236: A small molecule drug conjugate with an optimized camptothecin payload has significant activity in patient-derived and metastatic cancer models

CANCER RESEARCH

IF16.6

2023-04-040

PRE

Effective depletion of M2 macrophages by CD206-NAMPT-ADCs

CANCER RESEARCH

IF16.6

2020-08-150

PRE

Tailored Linker Chemistries for the Efficient and Selective Activation of ADCs with KSPi Payloads

BIOCONJUGATE CHEMISTRY

IF3.9

2020-07-1514

PREAI

A Selective Carborane-Functionalized Gastrin-Releasing Peptide Receptor Agonist as Boron Delivery Agent for Boron Neutron Capture Therapy

JOURNAL OF ORGANIC CHEMISTRY

IF3.6

2019-12-0940

PREAI

Preclinical characterization of BAY-924, a first in class ADC targeting CXCR5-positive B-cell malignancies, with a KSP inhibitor as novel payload

CANCER RESEARCH

IF16.6

2019-07-011

PRE

Improved safety profile of HER2-KSPi-ADCs compared to T-DM1 in in vitro megakaryocyte assay predictive of thrombocytopenia

CANCER RESEARCH

IF16.6

2019-07-010

PRE

KSPi-ADCs: ADCs with novel kinesin spindle protein inhibitor payloads and a tailor-made linker chemistry

CANCER RESEARCH

IF16.6

2019-07-010

PRE

Anti-tumor activity of BAY-943, an anti-IL3RA ADC with a novel KSP inhibitor payload, in CDX and PDX AML models

CANCER RESEARCH

IF16.6

2019-07-010

PRE

Antibody-Prodrug Conjugates with KSP Inhibitors and Legumain-Mediated Metabolite Formation

CHEMISTRY-A EUROPEAN JOURNAL

IF3.7

2019-04-1514

PREAI

Neutrophil Elastase Promotes Linker Cleavage and Paclitaxel Release from an Integrin-Targeted Conjugate

CHEMISTRY-A EUROPEAN JOURNAL

IF3.7

2018-12-2731

OAAI

Development of potent and selective antibody-drug conjugates with pyrrole-based KSP inhibitors as novel payload class

CANCER RESEARCH

IF16.6

2017-07-010

PRE

Preclinical activity of novel antibody-drug conjugates with pyrrole-based kinesin spindle protein inhibitors targeting different tumor antigens

CANCER RESEARCH

IF16.6

2017-07-010

PRE

Response of C4.4A-positive patient-derived xenograft models of ESCC, HNSCC and bladder cancer to BAY1129980, a C4.4A-targeted antibody drug conjugate

CANCER RESEARCH

IF16.6

2017-07-010

PRE

Neladenoson Bialanate Hydrochloride: A Prodrug of a Partial Adenosine A1 Receptor Agonist for the Chronic Treatment of Heart Diseases

IF3.4

2017-05-1042

PREAI

Preclinical Antitumor Efficacy of BAY 1129980-a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung Cancer

MOLECULAR CANCER THERAPEUTICS

IF5.5

2017-05-0238

OAAI